Loading clinical trials...

Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation | Clinical Trials | Clareo Health

COMPLETED

Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation

Clinical Efficacy and Safety of Tran-bronchoscopy Airway Clearance and Bronchoalveolar Lavage in the Treatment of Moderate to Severe Bronchiectasis With Acute Exacerbation

NCT03643302•Shanghai Pulmonary Hospital, Shanghai, China

View on ClinicalTrials.gov

Summary

No study have evaluated the efficacy and safety of airway clearance therapy (ACT) and bronchoalveolar lavage (BAL) under bronchoscope for bronchiectasis. This study aimed to evaluate the clinical efficacy and safety of tran-bronchoscopy airway clearance and bronchoalveolar lavage in the treatment of moderate to severe bronchiectasis with acute exacerbation:A randomized, prospective cohort study.

Detailed Description

The aim of this study was to evaluate the efficacy and safety of ACT combined with BAL for bronchiectasis patients with acute exacerbation through the whole study process, which will provide a high quality of evidence-based strategies for the treatment, revision and optimization of international and domestic clinical guidelines for bronchiectasis. All the participants will be required to check the various efficacy and safety indicators.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Willing to join in and sign the informed consent form;
•The diagnosis of bronchiectasis need reference to the definition of "European Respiratory Society guidelines for the management of adult bronchiectasis." published by the european respiratory journal in 2017, defined by the presence of both permanent bronchial dilatation on computed tomography (CT) scanning and the clinical syndrome of cough, sputum production and/or recurrent respiratory infections;
•Pulmonary exacerbation in patients with bronchiectasis was required to meet three or more of the following key symptoms for at least 48h: Cough; Sputum volume and/or consistency; Sputum purulence; Breathlessness and/or exercise tolerance; Fatigue and/or malaise; Haemoptysis, and a clinician determines that a change in bronchiectasis treatment is required;
•According to the researchers, the subjects were willing and able to follow the protocol and were able to tolerate bronchoscopy;
•Patients with good compliance: the subject must be willing to follow the test plan requirements in the research center to complete all the assessment of the visit.

Exclusion Criteria

•Pregnant or lactating women;
•Hypogammaglobulinemia or other autoimmune diseases;
•Clinical diagnosis of ABPA;
•Non tuberculosis mycobacteria positive 2 years before;
•Allergies or allergic to a variety of drugs;
•Poor compliance or can not cooperate judged by doctors;
•Participated in other clinical trials for nearly three months;
•The researchers considered that the subject had other circumstances that were unfit to attend;
•Suffering from a significant disease or condition outside of bronchiectasis, as judged by the researchers, may lead to subjects at risk due to participate in the study,or the disease that have an impact on the research result and the ability of subjects to participate in this study;
•Bronchoscopy contraindication;
+2 more criteria

Locations (1)

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

February 1, 2018

Primary Completion Date

February 28, 2019

Completion Date

March 18, 2019

Last Updated

October 8, 2020

Enrollment

189

ACTUAL participants

Conditions

Bronchiectasis Adult

Interventions

Version BF-1T26 electronic bronchoscope

DEVICE

Role of BARriers in IgG-Pathogen Interactions at the Mucosal Surface in Human Airways

NCT06670937

Bronchiectasis Adult

View study

RECRUITING

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

NCT06760273

Bronchiectasis Adult

View study

RECRUITING

A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation

Inclusion Criteria

Exclusion Criteria

Role of BARriers in IgG-Pathogen Interactions at the Mucosal Surface in Human Airways

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Effects of Expiratory Muscle Training Added to Pulmonary Rehabilitation in Patients With Bronchiectasis

Effect of AIRVO Heated Humidification in Bronchiectasis

Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production